symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CING,0.52,0,228375,9036976,0,0.485-1.93,0.01,Cingulate Inc.,USD,0001862150,US17248W1053,17248W105,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.cingulate.com,"Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.","Dr. Shane J. Schaffer Pharm.D., PharmD",Healthcare,US,15,913 942 2300,1901 West 47th Place,Kansas City,KS,66205,,0,https://financialmodelingprep.com/image-stock/CING.png,2021-12-08,False,False,True,False,False
